NCT01698216已完成不适用
Switching From Risperidone Long Acting Injection (Consta®) to Paliperidone Palmitate (Sustenna®) in Patients With Schizophrenia and Its Influence on Subjective Well-Being: A Prospective Observational Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Subjective Well-being Under Neuroleptic Treatment (SWN)
研究概览
简要总结
The aim of this study is observation of effectiveness and side effect of patients with schizophrenia who will switch the antipsychotics from risperidone long acting injection to paliperidone palmitate.
详细描述
In this study, investigators are going to enroll the patients who will switch the risperidone long acting injection to paliperidone palmitate. And investigators will examine the effectiveness and side effect of paliperidone palmitate. In addition, effectiveness and side effect related variables will be studied.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18 ~ 65
- •Patient with schizophrenia according to DSM-IV criteria
- •Patient have signed on the informed consent, and well understood the objective and procedure of this study.
- •Maintenance therapy more than 6 months with Risperidone Long Acting Injection monotherapy or other with concomitant antipsychotics, and stable dose of Risperidone Long Acting Injection was maintained 8 weeks more. The stable dose of other antipsychotics has been maintained 8 months and more.
- •Patient wants to switch antipsychotics to Paliperidone Palmitate.
- •PANSS total score ≤ 80
- •Each score of conceptual disorganization(P2), hallucinatory behavior(P3), Suspiciousness/persecution(P6), unusual thought content(G9)in PANSS ≤ 4
- •Competent patient who is manage to answer the questionnaires.
- •In case of female at child-bearing age, consent to use appropriate contraceptive methods(oral pill, contraceptive injection, intrauterine device, double barrier method and contraceptive patch) during entire duration of this study.
排除标准
- •No history of antipsychotics use.
- •Past history of NMS.
- •Allergy or hypersensitivity to Risperidone or Paliperidone ER.
- •Concomitant antipsychotics was oral Risperidone or Paliperidone ER.
- •Initiating or dose-changing of SSRI, MAOI, TCA within 2 months(maintenance is allowed if those have been stable for at least 30days prior to study entry and would not be any dose changes during the study)
- •Initiating of Lithium, Valproic acid, Carbamazepine, Topiramate, Lamotrigine or other mood stabilizer within 2months (maintenance is allowed).
- •Patient who is supposed to be impossible to participate to this study due to clinical risk of suicide or aggressive behavior based on clinician's opinion.
- •Current substance dependence(DSM-IV) or past history of dependence (more than 6months)
- •Significant biochemical or hematological abnormality or abnormal finding of urinalysis, based on clinician's opinion.
- •History of cardiac disease which predispose to QT prolongation(sick sinus, complete AV block, CHF, ventricular tachycardia, hypokalemia or hypocalcemia) or current medication of QT prolonging drugs
- •Pregnant or breast-feeding female patient.
- •History of participating to other investigational drug trial within 1month prior to screening.
- •Investigator or employee at clinical trial center, personnel related to investigator or trial center on this or other study, or family of employee or investigator
结局指标
主要结局
Subjective Well-being Under Neuroleptic Treatment (SWN)
时间窗: Change from Baseline in SWN score at 108 weeks
次要结局
- Visual Analog Scale(0,4,8,16,24,36,48,60,72,84,96,108 week)
- Korean Drug Attitude Inventory-10(Change from Baseline in score at 108 weeks)
- Positive and Negative Syndrome Scale(0,4,8,16,24,36,48,60,72,84,96,108 week)
- ECG(8, 24, 48, 72, 108 week)
- Personal and Social Performance Scale(0,4,8,16,24,36,48,60,72,84,96,108 week)
- Body weight(0,4,8,16,24,48,72,108 week)
- Clinical Global Impression-Severity, Improvement(0,4,8,16,24,36,48,60,72,84,96,108 week)
- Drug-Induced ExtraPyramidal Symptoms Scale(0,4,8,16,24,36,48,60,72,84,96,108 week)
- Symptom Check List-90-Revised(0,4,8,16,24,36,48,60,72,84,96,108 week)
- Liverpool University Neuroleptic Side Effect Rating Scale(0,4,8,16,24,36,48,60,72,84,96,108 week)
- blood pressure(0,4,8,16,24,48,72,108 week)
- waist circumference(0,4,8,16,24,48,72,108 week)
研究者
Yong Min Ahn
professor
Seoul National University Hospital
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaPsychotic DisorderSchizophreniaNCT00249119Janssen, LP1,579
已完成
3 期
Long-Acting Injectable Risperidone in the Treatment of SchizophreniaSchizophreniaSchizoaffective DisorderNCT00132314US Department of Veterans Affairs382
Unknown
4 期
PREvent First Episode Relapse (PREFER)SchizophreniaNCT00220714State University of New York - Downstate Medical Center80
已完成
不适用
Chiba Refractory Schizophrenia Treatment-LAI studyschizophrenia,schizoaffective disorderJPRN-UMIN000008487Department of Psychiatry, Graduate School of Medicine, Chiba University150
终止
4 期
Optimizing Response in Psychosis StudySchizophreniform DisorderPsychotic Disorder Not Otherwise SpecifiedSchizoaffective DisorderSchizophreniaNCT00314327Northwell Health1